The “Immunoscore” evaluated a combination of CD3+ and CD8+ TILs in both the tumor center and invasive front and showed the greatest impact on the risk of recurrence and death among the clinical parameters of colorectal cancer [11, 12]. This evidence concerns the gene CD8A and colorectal cancer.